Medicare Enrolled
Dr. Nishan Tchekmedyian, MD
Hematology & Oncology · Huntington Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tchekmedyian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tchekmedyian?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tchekmedyian
Dr. Nishan Tchekmedyian is a hematology & oncology specialist in Huntington Beach, CA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Tchekmedyian performed 3,281 Medicare services across 511 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tchekmedyian received a total of $58,070 from 45 pharmaceutical and/or device companies across 271 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tchekmedyian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice
▲ Top 36% volume in CA
$58,070 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,281
Medicare services
Top 36% in CA for hematology & oncology
511
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~219 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $82 |
| Anti-nausea injection (ondansetron/Zofran) | 376 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
346 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
251 | $88 | $352 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
139 | $14 | $93 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
77 | $18 | $88 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
61 | $136 | $514 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
57 | $12 | $81 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
53 | $121 | $606 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
51 | $59 | $269 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
42 | $1 | $4 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
32 | $12 | $69 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
29 | $30 | $220 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
28 | $1 | $22 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
28 | $2 | $9 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
27 | $26 | $99 |
| New patient office visit, complex (60-74 min) | 26 | $141 | $598 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
20 | $67 | $290 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
18 | $66 | $289 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.3% high complexity
78.6% medium
14.1% routine
Industry Payment Transparency
Open Payments through 2023 ↗$58,070
Total received (2018-2023)
Avg $11,614/year across 5 years
Top 11% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
271
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$51,114 (88.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,424 (9.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,531 (2.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$18
2021
$15,461
2020
$11,547
2019
$25,971
2018
$5,073
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$18
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
Foundation Medicine, Inc.
$43,628
Amgen Inc.
$7,694
Seattle Genetics, Inc.
$1,344
Spectrum Pharmaceuticals Inc.
$1,125
Janssen Biotech, Inc.
$493
AstraZeneca Pharmaceuticals LP
$467
Pharmacyclics LLC, An AbbVie Company
$371
Merck Sharp & Dohme Corporation
$328
Celgene Corporation
$318
Novartis Pharmaceuticals Corporation
$304
E.R. Squibb & Sons, L.L.C.
$296
PFIZER INC.
$176
GENZYME CORPORATION
$114
Bayer HealthCare Pharmaceuticals Inc.
$109
TerSera Therapeutics LLC
$99
Exelixis Inc.
$99
Genentech USA, Inc.
$96
Regeneron Healthcare Solutions, Inc.
$87
ARRAY BIOPHARMA INC
$82
Astellas Pharma US Inc
$65
AbbVie, Inc.
$60
MEDIVATION FIELD SOLUTIONS LLC
$56
TESARO, Inc.
$53
Lilly USA, LLC
$50
AMAG Pharmaceuticals, Inc.
$49
JAZZ PHARMACEUTICALS INC.
$45
Karyopharm Therapeutics Inc.
$43
GlaxoSmithKline, LLC.
$42
Takeda Pharmaceuticals U.S.A., Inc.
$42
Eisai Inc.
$42
INSYS Therapeutics Inc
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$25
MorphoSys, US Inc.
$24
Seagen Inc.
$23
AbbVie Inc.
$21
Incyte Corporation
$21
Daiichi Sankyo Inc.
$21
Ipsen Biopharmaceuticals, Inc
$20
Dova Pharmaceuticals
$19
Janssen Pharmaceuticals, Inc
$19
Teva Pharmaceuticals USA, Inc.
$18
Mylan Institutional Inc.
$16
EISAI INC.
$15
Innate Pharma, Inc
$13
Horizon Therapeutics plc
$11
Top 3 companies account for 90.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Alecensa · Aliqopa · Aranesp · BENDEKA · BRAFTOVI · Balversa · CABOMETYX · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELITEK · EMEND · EMPLICITI · Erleada · FASLODEX · FERAHEME · FOUNDATIONACT · FOUNDATIONONE · FOUNDATIONONE CDX · FOUNDATIONONE LIQUID · Fulphila · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRYSTEXXA · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · Lumoxiti · MONJUVI · MVASI · NINLARO · Nexavar · Nplate · Nubeqa · OPDIVO · PADCEV · PIQRAY · PROMACTA · Perjeta · Prolia · RYDAPT · Revlimid · SANDOSTATIN · SANDOSTATIN LAR · SOMATULINE DEPOT · SYNDROS · Stivarga · TAGRISSO · VARUBI · VENCLEXTA · VYXEOS · Venclexta · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · ZEJULA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (88%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
204
Per 100K population
6.4
County median income
$113,702
Nearest hospital
HUNTINGTON BEACH HOSPITAL
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tchekmedyian is a mixed practice specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 11% of CA peers, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tchekmedyian experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Tchekmedyian performed 1,620 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tchekmedyian receive payments from pharmaceutical companies?
Yes. Dr. Tchekmedyian received a total of $58,070 from 45 companies across 271 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tchekmedyian's costs compare to other hematology & oncology specialists in Huntington Beach?
Dr. Tchekmedyian's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tchekmedyian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Huntington Beach
Browse hematology & oncology specialists in Huntington Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Foundation Medicine, Inc. Payments to Doctors
See all physicians who received payments from Foundation Medicine, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology